Also in the MSK-Impact [9] and the Chinese Glioma Genome Atlas (CGGA) [23] there were too few samples and events to determine survival benefit in patients harbouring non-R132H IDH1/2–mutated tumours. This evidence concerns the gene IDH1 and central nervous system cancer.